ESMOImmuno25 – From Research to Practice
@myesmo.bsky.social
oncodaily.com/voices/esmoi...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMOImmuno25 #IO
@myesmo.bsky.social
oncodaily.com/voices/esmoi...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMOImmuno25 #IO
ESMOImmuno25 - From Research to Practice - OncoDaily
ESMOImmuno25 - From Research to Practice / cancer, cancer care, ESMO, ESMOImmuno25, European Society for Medical Oncology, OncoDaily, Oncology
oncodaily.com
September 24, 2025 at 3:01 PM
ESMOImmuno25 – From Research to Practice
@myesmo.bsky.social
oncodaily.com/voices/esmoi...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMOImmuno25 #IO
@myesmo.bsky.social
oncodaily.com/voices/esmoi...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMOImmuno25 #IO
'Neoadjuvant immunotherapy continues to rewrite our understanding of anticancer immunity'
Check out my #ESMODailyReporter editorial on some of the abstracts presented at this year's #ESMOImmuno25 in London 👇
Check out my #ESMODailyReporter editorial on some of the abstracts presented at this year's #ESMOImmuno25 in London 👇
#ESMODailyReporter: Jon Lim, MRCP PhD discusses the use of single-cell spatial transcriptomics and proteomic profiling to dissect why #immunotherapy works in some tumours but not others, highlighting neoadjuvant studies at #ESMOImmuno25 #ImmunoOncology
➡️ https://ow.ly/kwgt50XGX4M
➡️ https://ow.ly/kwgt50XGX4M
December 10, 2025 at 5:07 PM
'Neoadjuvant immunotherapy continues to rewrite our understanding of anticancer immunity'
Check out my #ESMODailyReporter editorial on some of the abstracts presented at this year's #ESMOImmuno25 in London 👇
Check out my #ESMODailyReporter editorial on some of the abstracts presented at this year's #ESMOImmuno25 in London 👇
📣 #ESMOImmuno25: Share your new data in a platform where early discoveries meet clinical implementation—accelerating progress from bench to bedside.
⏰ Submission deadline: 30 September 2025
🔗 buff.ly/1OcYcO5
⏰ Submission deadline: 30 September 2025
🔗 buff.ly/1OcYcO5
July 16, 2025 at 6:01 AM
📣 #ESMOImmuno25: Share your new data in a platform where early discoveries meet clinical implementation—accelerating progress from bench to bedside.
⏰ Submission deadline: 30 September 2025
🔗 buff.ly/1OcYcO5
⏰ Submission deadline: 30 September 2025
🔗 buff.ly/1OcYcO5
#ESMODailyReporter: Jon Lim, MRCP PhD discusses the use of single-cell spatial transcriptomics and proteomic profiling to dissect why #immunotherapy works in some tumours but not others, highlighting neoadjuvant studies at #ESMOImmuno25 #ImmunoOncology
➡️ https://ow.ly/kwgt50XGX4M
➡️ https://ow.ly/kwgt50XGX4M
December 10, 2025 at 4:12 PM
#ESMODailyReporter: Jon Lim, MRCP PhD discusses the use of single-cell spatial transcriptomics and proteomic profiling to dissect why #immunotherapy works in some tumours but not others, highlighting neoadjuvant studies at #ESMOImmuno25 #ImmunoOncology
➡️ https://ow.ly/kwgt50XGX4M
➡️ https://ow.ly/kwgt50XGX4M
📣#ESMOImmuno25: Check the programme and register today! Connect with global experts and explore innovative therapies that are shaping the future of oncology care.
⏰ Early registration deadline 8 October 2025
🔗 buff.ly/HbMTRxn
⏰ Early registration deadline 8 October 2025
🔗 buff.ly/HbMTRxn
June 9, 2025 at 7:01 AM
📣#ESMOImmuno25: Check the programme and register today! Connect with global experts and explore innovative therapies that are shaping the future of oncology care.
⏰ Early registration deadline 8 October 2025
🔗 buff.ly/HbMTRxn
⏰ Early registration deadline 8 October 2025
🔗 buff.ly/HbMTRxn
📣 #ESMOImmuno25: From research to practice, together we advance cancer care. Share your discoveries on a global stage and connect with leading researchers, clinicians and industry experts.
⏰ Abstract deadline: 30 September 2025
🔗 buff.ly/hSgCsLM
⏰ Abstract deadline: 30 September 2025
🔗 buff.ly/hSgCsLM
September 23, 2025 at 9:00 AM
📣 #ESMOImmuno25: From research to practice, together we advance cancer care. Share your discoveries on a global stage and connect with leading researchers, clinicians and industry experts.
⏰ Abstract deadline: 30 September 2025
🔗 buff.ly/hSgCsLM
⏰ Abstract deadline: 30 September 2025
🔗 buff.ly/hSgCsLM
✨ #ESMOImmuno25
@turajliclab.bsky.social presented the MANIFEST platform, recent progress & our ambitions at ESMO IO Congress here in London.
The message from the 'Special Session with Industry': cross-sector collaboration is critical to accelerate discovery & develop safer/effective therapies.
@turajliclab.bsky.social presented the MANIFEST platform, recent progress & our ambitions at ESMO IO Congress here in London.
The message from the 'Special Session with Industry': cross-sector collaboration is critical to accelerate discovery & develop safer/effective therapies.
December 10, 2025 at 4:58 PM
✨ #ESMOImmuno25
@turajliclab.bsky.social presented the MANIFEST platform, recent progress & our ambitions at ESMO IO Congress here in London.
The message from the 'Special Session with Industry': cross-sector collaboration is critical to accelerate discovery & develop safer/effective therapies.
@turajliclab.bsky.social presented the MANIFEST platform, recent progress & our ambitions at ESMO IO Congress here in London.
The message from the 'Special Session with Industry': cross-sector collaboration is critical to accelerate discovery & develop safer/effective therapies.
Really looking forward to catching up with colleagues and friends at #ESMOImmuno25 in London.
If you’re attending, please stop by our team’s poster - presented by our Specialist Pharmacist Ragini Jethra. We highlight new insights from our systematic review on the safety profile of TIL therapy.
If you’re attending, please stop by our team’s poster - presented by our Specialist Pharmacist Ragini Jethra. We highlight new insights from our systematic review on the safety profile of TIL therapy.
December 9, 2025 at 1:54 PM
Really looking forward to catching up with colleagues and friends at #ESMOImmuno25 in London.
If you’re attending, please stop by our team’s poster - presented by our Specialist Pharmacist Ragini Jethra. We highlight new insights from our systematic review on the safety profile of TIL therapy.
If you’re attending, please stop by our team’s poster - presented by our Specialist Pharmacist Ragini Jethra. We highlight new insights from our systematic review on the safety profile of TIL therapy.
The groundbreaking work behind the development of TCR mimics − ‘minibinders’ − is described by Sine Reker Hadrup in her Keynote Lecture at #ESMOImmuno25 and in an Opinion piece in the #ESMODailyReporter #ImmunoOncology
👉 https://ow.ly/jH9x50XHyFI
👉 https://ow.ly/jH9x50XHyFI
December 12, 2025 at 10:20 AM
The groundbreaking work behind the development of TCR mimics − ‘minibinders’ − is described by Sine Reker Hadrup in her Keynote Lecture at #ESMOImmuno25 and in an Opinion piece in the #ESMODailyReporter #ImmunoOncology
👉 https://ow.ly/jH9x50XHyFI
👉 https://ow.ly/jH9x50XHyFI
📣 #ESMOImmuno25: Inge Marie Svane, Scientific Co-Chair, invites you submit your data for a rich exchange of ideas and cross-pollination of innovation.
⏰ Deadline: 30 September 2025
🔗 buff.ly/Cjbu2oW
⏰ Deadline: 30 September 2025
🔗 buff.ly/Cjbu2oW
August 22, 2025 at 9:01 AM
📣 #ESMOImmuno25: Inge Marie Svane, Scientific Co-Chair, invites you submit your data for a rich exchange of ideas and cross-pollination of innovation.
⏰ Deadline: 30 September 2025
🔗 buff.ly/Cjbu2oW
⏰ Deadline: 30 September 2025
🔗 buff.ly/Cjbu2oW
📣 ESMOImmuno25: Aurélien Marabelle, Scientific Co-Chair, invites you to present your research to an international audience of top-tier scientists, clinicians, and industry experts.
⏰ Deadline: 30 September 2025
🔗 buff.ly/BsMH8pa
⏰ Deadline: 30 September 2025
🔗 buff.ly/BsMH8pa
August 7, 2025 at 8:57 AM
📣 ESMOImmuno25: Aurélien Marabelle, Scientific Co-Chair, invites you to present your research to an international audience of top-tier scientists, clinicians, and industry experts.
⏰ Deadline: 30 September 2025
🔗 buff.ly/BsMH8pa
⏰ Deadline: 30 September 2025
🔗 buff.ly/BsMH8pa
As Dimitrios A. Garyfallos shares new findings on, “In vivo CRISPR/Cas9 genetic screens identify novel immunotherapy target” at #ESMOImmuno25, discover more on CRISPR with #JITC!
December 10, 2025 at 5:30 PM
As Dimitrios A. Garyfallos shares new findings on, “In vivo CRISPR/Cas9 genetic screens identify novel immunotherapy target” at #ESMOImmuno25, discover more on CRISPR with #JITC!
📣 #ESMOImmuno25: Sergio Quezada, Scientific Co-Chair, encourages you to present your work in immuno-oncology to an engaged audience eager for innovative solutions.
⏰ Deadline: 30 September 2025
🔗 buff.ly/bw9eoBv
⏰ Deadline: 30 September 2025
🔗 buff.ly/bw9eoBv
September 9, 2025 at 8:30 AM
📣 #ESMOImmuno25: Sergio Quezada, Scientific Co-Chair, encourages you to present your work in immuno-oncology to an engaged audience eager for innovative solutions.
⏰ Deadline: 30 September 2025
🔗 buff.ly/bw9eoBv
⏰ Deadline: 30 September 2025
🔗 buff.ly/bw9eoBv
🔬 IMMUcan at #ESMOImmuno25
New multi-omics data from advanced TNBC patients treated with chemo-immunotherapy (SYNERGY & EORTC-1553-SPECTA) highlight how early tumor microenvironment changes shape outcomes.
New multi-omics data from advanced TNBC patients treated with chemo-immunotherapy (SYNERGY & EORTC-1553-SPECTA) highlight how early tumor microenvironment changes shape outcomes.
December 16, 2025 at 10:07 AM
🔬 IMMUcan at #ESMOImmuno25
New multi-omics data from advanced TNBC patients treated with chemo-immunotherapy (SYNERGY & EORTC-1553-SPECTA) highlight how early tumor microenvironment changes shape outcomes.
New multi-omics data from advanced TNBC patients treated with chemo-immunotherapy (SYNERGY & EORTC-1553-SPECTA) highlight how early tumor microenvironment changes shape outcomes.
📣 #ESMOImmuno25: Join Aurélien Marabelle, Inge Marie Svane, Sergio Quezada and the international community driving progress in immuno-oncology. 👉Register today and benefit from advantageous fees.
⏰ Deadline: 8 October 2025
🔗 buff.ly/FTpGSB1
⏰ Deadline: 8 October 2025
🔗 buff.ly/FTpGSB1
June 23, 2025 at 1:27 PM
📣 #ESMOImmuno25: Join Aurélien Marabelle, Inge Marie Svane, Sergio Quezada and the international community driving progress in immuno-oncology. 👉Register today and benefit from advantageous fees.
⏰ Deadline: 8 October 2025
🔗 buff.ly/FTpGSB1
⏰ Deadline: 8 October 2025
🔗 buff.ly/FTpGSB1
📣 #ESMOImmuno25: Your not-to-miss sessions! Scientific advances in immuno-biology focus, featuring discussions on personalised immunotherapies, new insight and approaches targeting regulatory T cells and more!
⏰ Register by 12 November and save! #esmomeetings
🔗 https://ow.ly/rryj50X7z1x
⏰ Register by 12 November and save! #esmomeetings
🔗 https://ow.ly/rryj50X7z1x
October 14, 2025 at 9:30 AM
📣 #ESMOImmuno25: Your not-to-miss sessions! Scientific advances in immuno-biology focus, featuring discussions on personalised immunotherapies, new insight and approaches targeting regulatory T cells and more!
⏰ Register by 12 November and save! #esmomeetings
🔗 https://ow.ly/rryj50X7z1x
⏰ Register by 12 November and save! #esmomeetings
🔗 https://ow.ly/rryj50X7z1x
#ESMOImmuno25 Awardee, Ignacio Melero, discusses how current #immunotherapy can be improved upon with the use of synergistic approaches including combination therapies and targeting resistance mechanisms. Full interview in the #ESMODailyReporter 👉 https://ow.ly/bgun50XGRUt
December 10, 2025 at 2:32 PM
#ESMOImmuno25 Awardee, Ignacio Melero, discusses how current #immunotherapy can be improved upon with the use of synergistic approaches including combination therapies and targeting resistance mechanisms. Full interview in the #ESMODailyReporter 👉 https://ow.ly/bgun50XGRUt
📣 #ESMOImmuno25: Stay ahead in the rapidly evolving field of immuno-oncology. Join the leading experts and pioneers that are driving progress in immuno-oncology.
⏰ Last chance to register and benefit from the best fees! Deadline 8 October 2025. #esmomeetings
🔗 https://ow.ly/ywTB50X7yOo
⏰ Last chance to register and benefit from the best fees! Deadline 8 October 2025. #esmomeetings
🔗 https://ow.ly/ywTB50X7yOo
October 7, 2025 at 9:30 AM
📣 #ESMOImmuno25: Stay ahead in the rapidly evolving field of immuno-oncology. Join the leading experts and pioneers that are driving progress in immuno-oncology.
⏰ Last chance to register and benefit from the best fees! Deadline 8 October 2025. #esmomeetings
🔗 https://ow.ly/ywTB50X7yOo
⏰ Last chance to register and benefit from the best fees! Deadline 8 October 2025. #esmomeetings
🔗 https://ow.ly/ywTB50X7yOo
📣 #ESMOImmuno25: Final call! Only 24 hours left to submit your studies.
Don’t miss your chance to connect with leading researchers, share your discoveries and contribute to shaping the future of cancer care.
⏰ Deadline 30 September
🔗 https://ow.ly/eN1p50X2GS5
Don’t miss your chance to connect with leading researchers, share your discoveries and contribute to shaping the future of cancer care.
⏰ Deadline 30 September
🔗 https://ow.ly/eN1p50X2GS5
September 29, 2025 at 11:00 AM
📣 #ESMOImmuno25: Final call! Only 24 hours left to submit your studies.
Don’t miss your chance to connect with leading researchers, share your discoveries and contribute to shaping the future of cancer care.
⏰ Deadline 30 September
🔗 https://ow.ly/eN1p50X2GS5
Don’t miss your chance to connect with leading researchers, share your discoveries and contribute to shaping the future of cancer care.
⏰ Deadline 30 September
🔗 https://ow.ly/eN1p50X2GS5
📣 All #ESMOImmuno25 congress sessions with speaker permission are now online for registered delegates & ESMO members on #OncologyPRO
👉 Watch on demand and stay at the forefront of oncology. #esmomeetings
🔗 https://ow.ly/7MwC50XHrLB
👉 Watch on demand and stay at the forefront of oncology. #esmomeetings
🔗 https://ow.ly/7MwC50XHrLB
December 16, 2025 at 4:30 PM
📣 All #ESMOImmuno25 congress sessions with speaker permission are now online for registered delegates & ESMO members on #OncologyPRO
👉 Watch on demand and stay at the forefront of oncology. #esmomeetings
🔗 https://ow.ly/7MwC50XHrLB
👉 Watch on demand and stay at the forefront of oncology. #esmomeetings
🔗 https://ow.ly/7MwC50XHrLB
#ESMOImmuno25: The next-generation PRAME-directed TCR T-cell therapy, IMA203CD8, showed encouraging activity not only in melanoma, but also in #OvarianCarcinoma and synovial sarcoma in a phase I #ClinicalTrial. Find out more in the #ESMODailyReporter ➡️ https://ow.ly/m30F50XHmHM
December 11, 2025 at 1:10 PM
#ESMOImmuno25: The next-generation PRAME-directed TCR T-cell therapy, IMA203CD8, showed encouraging activity not only in melanoma, but also in #OvarianCarcinoma and synovial sarcoma in a phase I #ClinicalTrial. Find out more in the #ESMODailyReporter ➡️ https://ow.ly/m30F50XHmHM
👉 #ESMOImmuno25: A. Marabelle, I.M. Svane and S. Quezada welcome you to the ESMO Immuno-Oncology Congress 2025, an international event to explore the science driving the next generation of cancer care.
#esmomeetings
🔗 buff.ly/jCNSjtl
#esmomeetings
🔗 buff.ly/jCNSjtl
December 10, 2025 at 11:15 AM
👉 #ESMOImmuno25: A. Marabelle, I.M. Svane and S. Quezada welcome you to the ESMO Immuno-Oncology Congress 2025, an international event to explore the science driving the next generation of cancer care.
#esmomeetings
🔗 buff.ly/jCNSjtl
#esmomeetings
🔗 buff.ly/jCNSjtl
🔬 IMMUcan at #ESMOImmuno25 | Poster Highlight II
Real-world data from early-stage #TNBC show evolving neoadjuvant practice across Europe:
⬇️ anthracyclines
⬆️ carboplatin & immunotherapy
📈 pCR rates, highest with KEYNOTE-522–like regimens and high TIL tumors
👉 www.immucan.eu
Real-world data from early-stage #TNBC show evolving neoadjuvant practice across Europe:
⬇️ anthracyclines
⬆️ carboplatin & immunotherapy
📈 pCR rates, highest with KEYNOTE-522–like regimens and high TIL tumors
👉 www.immucan.eu
December 18, 2025 at 10:57 AM
🔬 IMMUcan at #ESMOImmuno25 | Poster Highlight II
Real-world data from early-stage #TNBC show evolving neoadjuvant practice across Europe:
⬇️ anthracyclines
⬆️ carboplatin & immunotherapy
📈 pCR rates, highest with KEYNOTE-522–like regimens and high TIL tumors
👉 www.immucan.eu
Real-world data from early-stage #TNBC show evolving neoadjuvant practice across Europe:
⬇️ anthracyclines
⬆️ carboplatin & immunotherapy
📈 pCR rates, highest with KEYNOTE-522–like regimens and high TIL tumors
👉 www.immucan.eu
#ESMOImmuno25: Encouraging data reported with the PD-L1/TGF-β-targeting bifunctional fusion protein, SHR-1701, added to first-line CAPOX in an analysis of patients with #GastricCancer and high-risk features. More info in the #ESMODailyReporter ➡️ https://ow.ly/WF1450XHmqY
December 11, 2025 at 12:30 PM
#ESMOImmuno25: Encouraging data reported with the PD-L1/TGF-β-targeting bifunctional fusion protein, SHR-1701, added to first-line CAPOX in an analysis of patients with #GastricCancer and high-risk features. More info in the #ESMODailyReporter ➡️ https://ow.ly/WF1450XHmqY
At #ESMOImmuno25, Hans Nijman reports how “Neoadjuvant immune checkpoint inhibition skews the B cell response in mismatch repair deficient endometrial cancer”.
December 10, 2025 at 6:02 PM
At #ESMOImmuno25, Hans Nijman reports how “Neoadjuvant immune checkpoint inhibition skews the B cell response in mismatch repair deficient endometrial cancer”.